Philadelphia, PANCT07188090Now EnrollingIRB Ready

Multiple Myeloma Clinical Trial in Philadelphia, PA

Access cutting-edge multiple myeloma treatment through this phase 2 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Thomas Jefferson University

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access multiple myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple myeloma treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this multiple myeloma clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Multiple Myeloma Study in Philadelphia

This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been associated with a potentially higher incidence of engraftment syndrome. The trial aims to evaluate whether using G-CSF alone, with selective use of Plerixafor, can achieve adequate stem cell collection while possibly reducing the incidence of engraftment syndrome.

Sponsor: Thomas Jefferson University

Who Can Participate

Inclusion Criteria

Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:
Age ≥18 years
Undergoing autologous stem cell transplant for one of the following diagnoses:
Multiple myeloma
Hodgkin's lymphoma
Non-Hodgkin lymphoma
Karnofsky performance status of ≥ 60%
Patients must meet the TJUH BMT SOP guidelines for "Patient Criteria for Autologous HSCT" as specified below
Adequate organ function:
LVEF of ≥40%
Adjusted DLCO ≥45% of predicted corrected for hemoglobin
Adequate liver function as defined by a serum bilirubin \<1.8, AST or ALT \< 2.5X upper limit of normal
Serum creatinine ≤ 2.0 mg/dl and/or creatinine clearance of \> 40 ml/min (excludes multiple myeloma patients receiving high dose Melphalan conditioning)
Willingness to use contraception if childbearing potential
Has the ability to give informed consent, or for cognitively or decisionally impaired individuals (vulnerable population), the availability of a family member or guardian to give consent and assist in the consent process
Life expectancy of \> 12 months (exclusive of the disease for which the Auto HSCT is being performed)
Patients must have undergone stem cell mobilization with the combination of G- CSF or biosimilars with plerixafor or G-CSF or biosimilars alone

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:
Uncontrolled HIV
Uncontrolled bacterial infection
Active CNS disease
Pregnancy or lactation
Evidence of another malignancy, exclusive of a skin cancer that requires only local treatment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT07188090) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Myeloma Treatment Options in Philadelphia, PA

If you're searching for multiple myeloma treatment options in Philadelphia, PA, this clinical trial (NCT07188090) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Philadelphia, PA

See all multiple myeloma clinical trials recruiting in Philadelphia — not just this study.

Browse Multiple Myeloma Trials in Philadelphia →

Browse More Trials by Condition

Multiple Myeloma TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA